WebThis was a study of INCB052793 given to patients with advanced malignancies that was to be conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and Phase 1 had two parts; a dose escalation (Part 1) and an expansion (Part 2). Related Conditions: Acute Myeloid Leukemia Breast Carcinoma Cancer Lymphoma WebAn Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies. Status . Completed. Cancer Type . Breast Cancer Cancer-Related Syndrome Hematopoietic Malignancies Leukemia Lymphoma Multiple Myeloma Myelodysplastic Syndromes (MDS) Pancreatic Cancer Solid Tumor. Trial Phase .
Facebook - National Cancer Institute
http://mdedge.ma1.medscape.com/hematology-oncology/article/156512/multiple-myeloma/novel-jak1-inhibitor-shows-promise-myeloid WebINCB052793 has been studied in multiple myeloma (MM) preclinical models, but there are no reports using this agent in solid tumors. In combination with other anti-MM agents, INCB052793... cand vin ielele 2022
INCB 52793 - AdisInsight - Springer
WebProt #INCB 52793-101: A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies. Karmali, Reem (PD/PI) Kaplan, Jason B (Other) Medicine, Hematology Oncology Division; Project: Research project. Overview; Project Details Status: Finished ... WebOct 16, 2014 · This was a study of INCB052793 given to patients with advanced malignancies that was to be conducted in three phases; Phase 1a (Monotherapy) and … WebIncb052793 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating incb052793, 1 is phase 1/phase 2 (0 open). Complex karyotype, ER Negative, and ER No Expression are the most frequent biomarker inclusion criteria for incb052793 clinical trials. ... cand vine